Trevi Therapeutics, Inc.TRVINASDAQ
LOADING
|||
R&D Expense Growth Under Pressure
Trending lower.
Left:
||||
Year-over-year research & development expense growth
Latest
7.41%
↓ 11% below average
Average (31q)
8.37%
Historical baseline
Range
High:65.61%
Low:-27.39%
Volatility
1110.9%
High variability
| Period | Value |
|---|---|
| Q3 2025 | 7.41% |
| Q2 2025 | 20.20% |
| Q1 2025 | -16.26% |
| Q4 2024 | -16.89% |
| Q3 2024 | 12.00% |
| Q2 2024 | 13.82% |
| Q1 2024 | 35.07% |
| Q4 2023 | 3.08% |
| Q3 2023 | 8.23% |
| Q2 2023 | 16.84% |
| Q1 2023 | 15.82% |
| Q4 2022 | -25.17% |
| Q3 2022 | 13.05% |
| Q2 2022 | 9.86% |
| Q1 2022 | -24.83% |
| Q4 2021 | 30.97% |
| Q3 2021 | -27.39% |
| Q2 2021 | 16.26% |
| Q1 2021 | -14.80% |
| Q4 2020 | 35.87% |
| Q3 2020 | -1.89% |
| Q2 2020 | -18.24% |
| Q1 2020 | 24.80% |
| Q4 2019 | -14.64% |
| Q3 2019 | 2.21% |
| Q2 2019 | 65.61% |
| Q1 2019 | -26.20% |
| Q4 2018 | 20.71% |
| Q3 2018 | 8.96% |
| Q2 2018 | 45.54% |
| Q1 2018 | 47.87% |
| Q4 2017 | 0.00% |